β¨ Health Notices
4 APRIL 2013 NEW ZEALAND GAZETTE, No. 39 1187
Product: Nupentin
Active Ingredient: Gabapentin 300mg
Dosage Form: Capsule
New Zealand Sponsor: Mylan New Zealand Limited
Manufacturer: Alphapharm Pty Limited, Brisbane, Australia
Product: Nupentin
Active Ingredient: Gabapentin 400mg
Dosage Form: Capsule
New Zealand Sponsor: Mylan New Zealand Limited
Manufacturer: Alphapharm Pty Limited, Brisbane, Australia
Product: Simponi
Active Ingredient: Golimumab 50mg
Dosage Form: Solution for injection
New Zealand Sponsor: Janssen-Cilag (New Zealand) Limited
Manufacturer: Baxter Pharmaceutical Solutions LLC, Indiana, United States of America
Product: Simponi SmartJect Injector
Active Ingredient: Golimumab 50mg
Dosage Form: Solution for injection
New Zealand Sponsor: Janssen-Cilag (New Zealand) Limited
Manufacturer: Baxter Pharmaceutical Solutions LLC, Indiana, United States of America
Dated this 28th day of March 2013.
DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go1973
Misuse of Drugs Act 1975
Temporary Class Drug Notice
Pursuant to section 4E of the Misuse of Drugs Act 1975, I give notice that the following substances are renewed as temporary class drugs:
AM-1248
1-[(N-methylpiperidin-2-yl)methyl]-3-(adamant-1-oyl)indole
AM-2232
5-(3-(1-naphthoyl)-1H-indol-1-yl)pentanenitrile
UR-144
(1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone
This notice will take effect on 7 April 2013 and will expire on 6 April 2014, unless otherwise revoked as specified in section 4E of the Misuse of Drugs Act 1975.
Dated at Wellington this 28th day of March 2013.
HON PETER DUNNE, Associate Minister of Health.
go1985
Temporary Class Drug Notice
Pursuant to section 4E of the Misuse of Drugs Act 1975, I give notice that the following substance is renewed as a temporary class drug:
DMAA
1,3-dimethylamylamine or 4-methylhexane-2-amine
This notice will take effect on 10 April 2013 and will expire on 9 April 2014, unless otherwise revoked as specified in section 4E of the Misuse of Drugs Act 1975.
Dated at Wellington this 28th day of March 2013.
HON PETER DUNNE, Associate Minister of Health.
go1986
Next Page →
β¨ LLM interpretation of page content
π₯
Consent to the Distribution of New Medicines - Nupentin and Simponi
(continued from previous page)
π₯ Health & Social Welfare28 March 2013
Medicines Act, New Medicines, Distribution Consent, Nupentin, Simponi, Gabapentin, Golimumab
- Dr Don Mackie, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health
π₯ Temporary Class Drug Notice - AM-1248, AM-2232, UR-144
π₯ Health & Social Welfare28 March 2013
Misuse of Drugs Act, Temporary Class Drugs, AM-1248, AM-2232, UR-144
- Hon Peter Dunne, Associate Minister of Health
π₯ Temporary Class Drug Notice - DMAA
π₯ Health & Social Welfare28 March 2013
Misuse of Drugs Act, Temporary Class Drugs, DMAA
- Hon Peter Dunne, Associate Minister of Health
NZ Gazette 2013, No 39